

Product Description

Pioneering GTPase and Oncogene Product Development since 2010

CCL23 RABBIT PAB

货号: S220429 产品全名: CCL23 兔多抗

基因符号 CKb8; MIP3; Ckb-8; MIP-3; MPIF-1; SCYA23; Ckb-8-1; hmrp-2a; CK-BETA-8

UNIPROT ID: P55773 (Gene Accession - NP_005055)

背景: This gene is one of several chemokine genes clustered on the q-arm of chromosome 17. Chemokines form a superfamily of secreted proteins involved in immunoregulatory and inflammatory processes. The superfamily is divided into four subfamilies based on the arrangement of the N-terminal cysteine residues of the mature peptide. This chemokine, a member of the CC subfamily, displays chemotactic activity on resting T lymphocytes and monocytes, lower activity on neutrophils and no activity on activated T lymphocytes. The protein is also a strong suppressor of colony formation by a multipotential hematopoietic progenitor cell line.

抗原: Synthetic peptide of human CCL23

经过测试的应用: ELISA, IHC

推荐稀释比: IHC: 50-200; ELISA: 1000-5000 种属反应性: Rabbit

克隆性: Rabbit Polyclonal

亚型: Immunogen-specific rabbit IgG


纯化: Antigen affinity purification

种属反应性: Human


成分: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

研究领域: Signal Transduction, Immunology


储存和运输: Store at -20°C. Avoid repeated freezing and thawing



Immunohistochemistry analysis of paraffin embedded Human Lymphoma tissue using 220429(CCL23 Antibody) at a dilution of 1/50(Cytoplasm).



In comparision with the IHC on the left, the same paraffin-embedded Human Lymphoma tissue is first treated with the synthetic peptide and then with 220429(Anti-CCL23 Antibody) at dilution 1/50.



The image on the left is immunohistochemistry of paraffinembedded Human lung cancer tissue using 220429(Anti-CCL23 Antibody) at a dilution of 1/50.

In comparision with the IHC on the left, the same paraffin-embedded Human lung cancer tissue is first treated with synthetic peptide and then with D261518(Anti-CCL23 Antibody) at dilution 1/50.



Product Description

Pioneering GTPase and Oncogene Product Development since 2010